Leerink Swann started coverage on shares of Vericel (NASDAQ:VCEL) in a research note released on Wednesday morning, Marketbeat reports. The firm issued an outperform rating and a $15.00 price objective on the biotechnology company’s stock. Leerink Swann also issued estimates for Vericel’s Q1 2018 earnings at ($0.12) EPS, Q2 2018 earnings at ($0.05) EPS, Q3 2018 earnings at ($0.09) EPS, Q4 2018 earnings at $0.02 EPS, FY2018 earnings at ($0.24) EPS, Q1 2019 earnings at ($0.08) EPS, Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at $0.08 EPS, FY2019 earnings at ($0.05) EPS, FY2020 earnings at $0.11 EPS, FY2021 earnings at $0.32 EPS and FY2022 earnings at $0.50 EPS.
A number of other analysts have also issued reports on the stock. ValuEngine upgraded shares of Vericel from a hold rating to a buy rating in a research note on Monday, April 2nd. BidaskClub downgraded shares of Vericel from a strong-buy rating to a buy rating in a report on Friday, March 30th. Needham & Company LLC lifted their price objective on shares of Vericel from $5.00 to $15.00 and gave the stock a buy rating in a report on Tuesday, March 6th. Ladenburg Thalmann downgraded shares of Vericel from a buy rating to a neutral rating in a report on Tuesday, March 6th. Finally, BTIG Research reaffirmed a buy rating and issued a $13.00 price objective (up previously from $8.00) on shares of Vericel in a report on Monday, March 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $14.25.
Shares of NASDAQ:VCEL opened at $11.20 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.86 and a quick ratio of 3.57. The firm has a market capitalization of $402.65, a P/E ratio of -22.40 and a beta of 3.18. Vericel has a 12-month low of $2.35 and a 12-month high of $12.80.
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its holdings in Vericel by 35.2% in the fourth quarter. Bank of New York Mellon Corp now owns 44,188 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 11,509 shares during the period. Perkins Capital Management Inc. boosted its holdings in Vericel by 2.9% in the fourth quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock worth $3,155,000 after purchasing an additional 16,350 shares during the period. Goldman Sachs Group Inc. acquired a new position in Vericel in the fourth quarter worth $105,000. Bank of Montreal Can acquired a new position in Vericel in the fourth quarter worth $140,000. Finally, Geode Capital Management LLC boosted its holdings in Vericel by 11.9% in the fourth quarter. Geode Capital Management LLC now owns 255,168 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 27,226 shares during the period. 37.22% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3340150/vericel-vcel-earns-outperform-rating-from-analysts-at-leerink-swann.html.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.